Ipilimumab Approaches EU Approval for Pediatric Melanoma

December 18, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of ipilimumab for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor. The application is based on data across 2 trials in which objective responses were observed in 2 of 17 patients aged … (leggi tutto)